In the wake of Thermo Fisher Scientific, Inc.’s TMO impending acquisition of Affymetrix, Inc. AFFX, the latter has finally chosen to stick to Thermo Fisher’s $1.3 billion takeover bid. With this ...
Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue ...
SAN DIEGO & SANTA CLARA, Calif., Jan 10, 2008 - Affymetrix and Illumina, Inc. (NASDAQ:ILMN) announced today that they have entered into a settlement agreement to resolve their patent litigation. Under ...
On June 25, genetic products maker Affymetrix Inc (AFFX) completed its acquisition of eBioscience Holding Company, Inc. for $315 million in cash. The payment was partly financed through available cash ...
What: After reporting that it's sticking with a previous deal to be acquired by Thermo Fisher Scientific, (TMO-0.07%) and rejecting a higher, competing offer, shares in Affymetrix(AFFX.DL) are down ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (Nasdaq: AFFX) today announced that Dr. Frank Witney has been appointed president and chief executive officer, effective July 1, 2011. Dr. Witney ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a definitive agreement to acquire Panomics Inc., a privately held Fremont, Calif.-based ...
Affymetrix Inc. on Wednesday postponed a vote on its proposed tie-up with Thermo Fisher Scientific Inc.,TMO-1.64%decrease; red down pointing triangle saying a new unsolicited bid from Origin ...
Affymetrix expects the acquisition of eBioscience to: • Create significant new commercial opportunities in the key post-genomic applications of immunology, oncology, cell biology, stem cell biology, ...
Affymetrix, Inc. has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results